Startup Scout 13 Jan 2017 The Good, the Bad and the Cancer-Fighting Macrophage We decided to stick around England this week and made a short trip from London to visit the young biotech Macrophage Pharma. The company is developing immuno-oncology technology that could turn ‘bad’ tumor-associated macrophages into ‘good’, cancer-fighting cells. City: Berkhamsted, UK (near London) Founded: 2014 Employees: 1-10 Financial data: €10.38M total raised Mission: Macrophage Pharma develops next-generation immunotherapies […] January 13, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2017 Merck expands its Oncology Pipeline beyond Checkpoint Inhibitors Merck is diversifying its oncology portfolio with four new programs licensed from Vertex Pharmaceuticals, including multiple DNA damage and repair drugs. Merck has entered a licensing agreement with Boston-based Vertex Pharmaceuticals for the worldwide rights to four oncology programs. Merck has paid €220M ($230M) upfront for two clinical-stage DNA damage and repair candidates and two additional […] January 11, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2017 Servier offers up to €1.7B for Dual Cancer Checkpoint Inhibitors Servier has signed a deal that could give it access to up to eight bispecific drug candidates with immuno-oncology applications from Pieris Pharmaceuticals. Servier, one of France’s biggest pharma companies, is offering up to €1.7B to US-based Pieris Pharmaceuticals. The team will initially develop five programs that can be later expanded to up to eight. For […] January 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2017 New German Immuno-oncology Partnership takes on Solid Tumors TCR2 Therapeutics is initiating a partnership with academia to boost its TCR technology with the aim of overcoming the huge challenges of treating solid tumors. TCR2 Therapeutics, a Boston immuno-oncology startup launched in 2015 and funded by the Munich biotech mafia, is starting the year with a multi-year collaboration with the University Hospital of Ludwig-Maximilians-University (LMU) in, […] January 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Jan 2017 10 Hot European Biotechs to Observe in 2017 🚀 New year, new list: here are the 10 hottest Biotech companies I will watch closely in 2017 and why. This list is not meant to be comprehensive and is in no particular order. Super-pumped mRNA Therapy BioNTech is Europe’s largest private Biotech with over 500 employees and is one of the three leading mRNA therapy […] January 3, 2017 - 5 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
Interview 2 Jan 2017 The Story behind one of the Most Successful Danish Biotech Entrepreneurs The series of profiles on impressive biotech leaders continues: John Haurum founded one of the most successful biotech companies in Denmark and is now leading one of the hottest European immuno-oncology companies. Here are some of his lessons and thoughts looking back at his rich career. John Haurum, born in Denmark, studied medicine at Aarhus University […] January 2, 2017 - 6 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 22 Dec 2016 BMS Offers €850M for a British Oncolytic Virus better than CAR-T BMS is offering PsiOxus Therapeutics a massive deal to get exclusive rights of an oncolytic virus that could outperform the promising CAR-T therapies. PsiOxus Therapeutics, based in Oxford, develops immuno-oncolytic viruses to treat solid tumors. Its technology attracted a partnership with Bristol-Myers Squibb earlier this year, which is now offering the British biotech an impressive €850M […] December 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Dec 2016 The 10 Biggest Clinical Success Stories of 2016 in European Biotech What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here’s a list of the best success stories of 2016. Biotech is becoming a powerful driving force in medicine, providing innovative therapies that could end some of the most severe diseases. To celebrate the advances in the area of […] December 22, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2016 These are our 10 Most Read Biotech Articles of 2016 From the hottest research areas to the most popular city for biotech, which biotech articles have managed to hook our readers the most this year? After an exciting journey of 2 years, Labiotech.eu is now the leading biotech media in Europe, with over 50k monthly readers. To celebrate the end of another amazing year, we wanted […] December 20, 2016 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2016 Young Immuno-Oncology Biotechs attract Funding to Cure Metastasis Amcure and TILT Biotherapeutics announced yesterday new financing rounds supporting the development of unique strategies to cure cancer metastasis. Amcure, in Germany, is fighting highly metastatic forms of cancer by targeting angiogenesis. The company just closed a Series B round with a total of €6M from already existing investors. With the funds, Amcure plans to accelerate […] December 16, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Dec 2016 Curing Cancer with Safer Transplants: UK Approval to start Clinical Trials Kiadis Pharma has received approval to test in the UK an immune therapy to address the big challenges of bone marrow transplants, currently the only cure for blood cancers. Kiadis Pharma, based in Amsterdam, is working on therapies to improve the outcome of hematopoietic stem cell transplantation (HSCT), a common treatment for multiple types of […] December 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2016 Swedish Therapy targeting All Solid Tumors enrolls First Patient Immunicum just received FDA approval to start clinical trials in the US for a therapy that could overcome the challenges of T-cell therapies and target virtually any injectable solid tumor. Immunicum is a biotech from Gothenburg, Sweden, that focuses on immuno-oncology with a different approach from most companies. Instead of T-cells, the company engineers dendritic […] December 14, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email